CYTLIMIC
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune systems to attack cancer cells while enabling patients to maintain a high quality-of-life during treatment.
CYTLIMIC
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2016-12-16
Address:
Higashi-shinagawa, Tokyo, Japan
Country:
Japan
Website Url:
http://www.cytlimic.com
Total Employee:
1+
Status:
Active
Total Funding:
20.85 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx
Current Advisors List
Current Employees Featured
Founder
Investors List
SMBC Venture Capital
SMBC Venture Capital investment in Series B - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series B - Cytlimic
NEC Capital Solutions
NEC Capital Solutions investment in Series B - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Seed Round - Cytlimic
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Series A - Cytlimic
NEC Capital Solutions
NEC Capital Solutions investment in Series A - Cytlimic
SMBC Venture Capital
SMBC Venture Capital investment in Series A - Cytlimic
Official Site Inspections
http://www.cytlimic.com
- Host name: 150.95.255.38
- IP address: 150.95.255.38
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Cytlimic"
Cytlimic - Crunchbase Company Profile & Funding
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC’s products aim to activate immune …See details»
CYTLIMIC Company Profile - Office Locations, Competitors ... - Craft
CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer. It specializes in clinical trials and nonclinical testing of cancer peptide vaccines as well …See details»
Cytlimic Company Profile 2024: Valuation, Funding & Investors
Cytlimic is headquartered in Tokyo, Japan. What industry is Cytlimic in? Cytlimic’s primary industry is Drug Discovery. Is Cytlimic a private or public company? Cytlimic is a Private …See details»
CYTLIMIC, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Explore CYTLIMIC, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news, and 5 literature, Disease Domain:Neoplasms, Technology …See details»
Cytlimic - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Cytlimic . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Employee Profiles 2. Number of Board Member and Advisor Profiles 5. …See details»
CYTLIMIC Inc - Company Profile and News - Bloomberg Markets
Company profile page for CYTLIMIC Inc including stock price, company news, executives, board members, and contact informationSee details»
Cytlimic - Crunchbase
CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. Search Crunchbase Start Free TrialSee details»
NEC ventures into the drug discovery business: pursuing the …
On December 19, 2016, as part of efforts to strengthen its healthcare business, NEC announced the establishment of CYTLIMIC Inc., a new company that promotes the development and …See details»
CYTLIMIC - Products, Competitors, Financials, Employees, …
About CYTLIMIC. CYTLIMIC is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide vaccine. CYTLIMIC's products aim to …See details»
NEC drug development investment, CYTLIMIC, secures 1.3 billion …
Aug 9, 2019 NEC Corporation (NEC; TSE: 6701) and CYTLIMIC Inc. today announced that financing of 1.3 billion yen (around US$ 12 million at current rate) was completed through the …See details»
NEC aims to discover new drugs harnessing advanced AI technology
Tokyo, December 19, 2016 - NEC Corporation (NEC; TSE: 6701) today announced the establishment of "CYTLIMIC Inc." (CYTLIMIC), a new company that promotes the …See details»
Cytlimic - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Aug 9, 2019: Series B - …See details»
CYTLIMIC For personal use only - Australian Securities Exchange
Jan 7, 2019 CYTLIMIC’s current lead product candidate CYT001 is a combination of two multiple-HLA peptides for HSP70 and GPC3 antigens, and LAG-3Ig (Eftilagimod Alpha) and …See details»
PRIMA BIOMED ENTERS NEW MATERIAL TRANSFER AGREEMENT …
CYTLIMIC, a recent spin off from NEC Corporation (NEC), is a biotechnology company developing immunotherapy products for the treatment of cancer, including a cancer peptide …See details»
Phase I study of a new concept cancer vaccine composed artificial ...
Background: CYT001 (CYTLIMIC Inc.) is a novel cancer vaccine involving artificial intelligence (AI)-designed shared-antigen peptides and optimal combined adjuvants that boost the cancer …See details»
Cytlimic - Updates, News, Events, Signals & Triggers - Crunchbase
CYTLIMIC is a biotechnology company that develops immunotherapy products for the treatment of cancer, including a cancer peptide vaccine.See details»
CYTLIMIC, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
May 30, 2023 Explore CYTLIMIC, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news.See details»
Immutep Enters into Clinical Trial Collaboration, Service and …
Jan 7, 2019 CYTLIMIC also has unique intellectual properties of a combination of LAG-3 IgG fusion protein and Poly IC to synergistically boost the effect of peptide vaccine antigens. …See details»
Cytlimic - Tech Stack, Apps, Patents & Trademarks - Crunchbase
The intellectual property of Cytlimic includes 5 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, Cytlimic has …See details»
Immutep Enters Into Clinical Trial Collaboration, Service
Jan 7, 2019 CYTLIMIC’s current lead product candidate CYT001 is a combination of two multiple-HLA peptides for HSP70 and GPC3 antigens, and LAG-3Ig (Eftilagimod Alpha) and …See details»